Boxer Capital LLC Has $12,813,000 Stake in Alnylam Pharmaceuticals, Inc. (ALNY)

Boxer Capital LLC held its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 250,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Alnylam Pharmaceuticals comprises 2.8% of Boxer Capital LLC’s holdings, making the stock its 10th largest position. Boxer Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $12,813,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its stake in Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 36 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares during the last quarter. Swiss National Bank increased its stake in Alnylam Pharmaceuticals by 0.6% in the first quarter. Swiss National Bank now owns 127,700 shares of the biopharmaceutical company’s stock valued at $6,545,000 after buying an additional 800 shares during the last quarter. Pacer Advisors Inc. increased its stake in Alnylam Pharmaceuticals by 19.4% in the first quarter. Pacer Advisors Inc. now owns 9,517 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 1,544 shares during the last quarter. Finally, Macquarie Group Ltd. increased its stake in Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 1,614 shares during the last quarter. Institutional investors and hedge funds own 90.04% of the company’s stock.

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up 0.96% on Friday, reaching $76.07. The company had a trading volume of 1,264,505 shares. Alnylam Pharmaceuticals, Inc. has a 1-year low of $31.38 and a 1-year high of $80.11. The firm’s market capitalization is $6.56 billion. The firm has a 50-day moving average price of $65.34 and a 200 day moving average price of $50.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The firm had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. The firm’s revenue was up 160.3% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.21) earnings per share. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.31) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Boxer Capital LLC Has $12,813,000 Stake in Alnylam Pharmaceuticals, Inc. (ALNY)” was originally published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.wkrb13.com/markets/2228899/boxer-capital-llc-has-12813000-stake-in-alnylam-pharmaceuticals-inc-alny.html.

Several brokerages have recently issued reports on ALNY. Chardan Capital set a $95.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 5th. BMO Capital Markets began coverage on Alnylam Pharmaceuticals in a report on Monday, April 17th. They issued an “outperform” rating and a $73.00 price objective for the company. Vetr cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price objective for the company. in a report on Monday, May 15th. Ladenburg Thalmann Financial Services set a $80.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 17th. Finally, Leerink Swann reissued a “market perform” rating and issued a $67.00 price objective (up previously from $53.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, May 17th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $71.29.

In related news, major shareholder Sanofi acquired 297,501 shares of the stock in a transaction dated Wednesday, May 31st. The stock was bought at an average cost of $71.87 per share, with a total value of $21,381,396.87. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Akshay Vaishnaw sold 43,750 shares of the business’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the sale, the senior vice president now directly owns 43,047 shares of the company’s stock, valued at $2,798,055. The disclosure for this sale can be found here. Insiders sold a total of 64,125 shares of company stock valued at $4,325,000 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228899/boxer-capital-llc-has-12813000-stake-in-alnylam-pharmaceuticals-inc-alny.html

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.